Louisiana lawmakers are considering legislation that would classify the abortion-inducing drugs mifepristone and misoprostol as controlled dangerous substances, meaning that possession of these drugs without a prescription could lead to fines or jail time.
During oral arguments March 26 about the public’s access to the abortion pill mifepristone, the Supreme Court justices seemed likely to reject a challenge to the drug’s availability.
The United States Supreme Court is beginning deliberations March 26 concerning the Biden administration’s handling of safeguards related to the use of the chemical abortion drug mifepristone and its potential risks to women.
In response to the upcoming Supreme Court case about access to the commonly used abortion pill, mifepristone, the U.S. bishops are calling on Catholics across the country to pray for an end to abortion.
The Supreme Court agreed Dec. 13 to look at a dispute over the availability of a commonly used abortion pill, mifepristone, making it the first abortion case it will hear since its decision overturning Roe v. Wade last year.
The number of legal abortions provided by virtual-only clinics via abortion pill prescriptions spiked 72% in the year following the Supreme Court’s reversal of Roe v. Wade, according to a report by #WeCount, a research project by the Society of Family Planning, a group that supports legal abortion.
In a two-hour hearing on May 17 looking at the U.S. Food and Drug Administration’s decades-old approval of an abortion pill, federal judges seemed to have a harsher line of questioning for attorneys for the federal government and the drug maker, indicating they might be sympathetic to those challenging the drug’s availability.
A federal appeals court in Louisiana is hearing arguments May 17 about the accessibility of the abortion drug mifepristone.
An advisory panel of the Food and Drug Administration voted unanimously on May 10 to recommend that a birth control pill be sold in the U.S. without a doctor’s prescription.
The U.S. Supreme Court said it would extend the administrative stay in the abortion pill dispute until April 21, temporarily keeping in place status quo federal regulations regarding the use of an abortion drug, and giving the court additional time to consider a lower court’s ruling to stay the U.S. Food and Drug Administration’s approval of the drug.
